Figure 5:
Nonresponder imputation analysis of symptomatic remission and corticosteroid-free symptomatic remission†, ‡, §, ¶ at Week 92; patients randomized to ustekinumab in the maintenance study and treated in the long-term extension
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.